Agios Pharmaceuticals, Inc. (AGIO) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Agios Pharmaceuticals’s revenue went from $70M in fiscal 2016 to $54M in fiscal 2025, a decline of about 2.8% a year.
Net income in fiscal 2025 was -$413M, a net margin of -764.0%; the best year in this period was 2021 with $1.6B.
Over the twelve months to September 30, 2026, revenue was $141M and net income -$373M.
Free cash flow was -$377M in fiscal 2025 and positive in 1 of the 10 years shown.
The diluted share count rose 48% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141M | $54M | — | $27M | $14M | — | $0 | $118M | $94M | $43M | $70M |
| Gross profit | $132M | $48M | — | $24M | $13M | — | $0 | $117M | $93M | $43M | $70M |
| Operating income | -$419M | -$472M | -$426M | -$391M | -$389M | -$378M | -$336M | -$316M | -$362M | -$321M | -$201M |
| Net income | -$373M | -$413M | $674M | -$352M | -$232M | $1.6B | -$327M | -$411M | -$346M | -$315M | -$198M |
| EPS (diluted) | $-6.32 | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | $-6.03 | $-6.75 | $-5.07 |
| R&D | $343M | $340M | $301M | $296M | $280M | $257M | $221M | $214M | $341M | $293M | $220M |
| Revenue growth | — | — | — | +88.4% | — | — | −100.0% | +24.9% | +119.4% | −38.5% | +18.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$332M | -$373M | -$390M | -$296M | -$309M | -$407M | -$291M | -$371M | -$304M | -$285M | $39M |
| Capital spending | -$4M | -$4M | -$2M | -$999000 | -$5M | -$6M | -$14M | -$12M | -$7M | -$5M | -$10M |
| Free cash flow | -$336M | -$377M | -$392M | -$297M | -$314M | -$413M | -$305M | -$383M | -$311M | -$290M | $29M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | $0 | $0 | $802M | $0 | $0 | — | — | — |
| Stock-based pay | $62M | $53M | $43M | $45M | $49M | $54M | $62M | $58M | $73M | $48M | $42M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $854M | $894M | $777M | $783M | $1.0B | $573M | $565M | $585M | $103M | $541M |
| Debt | — | $40M | $57M | $72M | $86M | $96M | $105M | $113M | $0 | $0 | $0 |
| Equity | — | $1.2B | $1.5B | $811M | $1.1B | $1.3B | $400M | $641M | $688M | $376M | $359M |
| Total assets | — | $1.3B | $1.7B | $937M | $1.2B | $1.4B | $853M | $891M | $858M | $614M | $619M |
| Shares (diluted) | 60M | 58M | 58M | 56M | 55M | 60M | 69M | 60M | 57M | 47M | 39M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 93.8% | 88.3% | — | 89.3% | 88.0% | — | — | 98.9% | 98.5% | 100.0% | 100.0% |
| Operating margin | -297.7% | -873.9% | — | -1459.5% | -2732.1% | — | — | -268.2% | -384.0% | -745.8% | -287.6% |
| Net margin | -264.8% | -764.0% | — | -1312.6% | -1627.8% | — | — | -349.0% | -366.6% | -731.6% | -284.0% |
| FCF margin | -238.5% | -698.3% | — | -1107.5% | -2207.6% | — | — | -324.5% | -329.9% | -673.9% | 41.0% |
| ROIC | — | -38.2% | -25.0% | -44.3% | -32.8% | -21.5% | -52.6% | -42.0% | -52.7% | -85.4% | -56.0% |
| ROE | — | -34.6% | 43.7% | -43.4% | -21.1% | 124.2% | -81.9% | -64.2% | -50.3% | -83.8% | -55.4% |
Frequently asked questions
What is Agios Pharmaceuticals’s annual revenue?
$54M in fiscal 2025 and $141M over the twelve months to September 30, 2026.
How much profit does Agios Pharmaceuticals make?
Net income was -$413M in fiscal 2025 (net margin -764.0%).
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.